Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
UNITED STATES OF AMERICA EX REL BRUCE BOISE ET AL VS CEPHALON, INC.ET AL
Case Number:
2:08-cv-00287
Court:
Nature of Suit:
Other Statutes: Other Statutory Actions
Judge:
Firms
- Baron & Budd
- Blank Rome
- Campbell Conroy
- Lieff Cabraser
- Morgan Lewis
- Patterson Belknap
- Tanenbaum Keale
- Weinstein Kitchenoff
Companies
Sectors & Industries:
-
March 16, 2017
Cephalon Settles FCA Suit Over Provigil Marketing
Cephalon Inc. has settled a whistleblower's False Claims Act suit over the company's alleged off-label promotion of its narcolepsy drug Provigil, according to an order filed in Pennsylvania federal court Thursday.
-
February 02, 2016
Cephalon Trims 1 Year Of Provigil Claims In FCA Suit
A Pennsylvania federal judge agreed Tuesday to peel a year's worth of claims from consolidated litigation over Cephalon Inc.'s alleged off-label promotion of its narcolepsy drug Provigil, finding that the federal government's decision not to intervene in the False Claims Act case triggered a six-year statute of limitations.
-
July 30, 2015
Cephalon Can't Dodge Provigil Claims In FCA Off-Label Suit
A Pennsylvania federal judge Thursday denied a bid by Cephalon Inc. to dismiss claims in a False Claims Act suit relating to off-label marketing of its drug Provigil, saying a recent high court ruling did not support Cephalon's assertion that similar claims in a related whistleblower suit barred the instant claims.
-
July 21, 2015
Cephalon Can't Ditch FCA Claims In Off-Label Marketing Suit
A Pennsylvania federal judge on Tuesday refused Cephalon Inc.'s bid to dismiss claims in a False Claims Act dispute alleging the pharmaceutical company improperly promoted drugs for off-label uses, finding the relators properly stated a claim concerning its corporate integrity agreement.
-
April 15, 2015
Cephalon Thins FCA Off-Label Marketing, Kickback Suit
A Pennsylvania federal judge pared charges Wednesday from a False Claims Act case alleging pharmaceutical company Cephalon Inc. improperly promoted drugs for off-label uses, saying some state law claims could not be prosecuted but allowing key federal charges to continue.
-
March 31, 2015
Cephalon Wants FCA Off-Label Marketing Claims Axed
Pharmaceutical company Cephalon Inc. urged a Pennsylvania federal judge on Tuesday to nix a pair of whistleblower suits accusing it of spurring false reimbursement claims to the government through a scheme to promote three of its drugs off-label.
-
November 06, 2014
Cephalon Wants FCA Off-Label Suits Heard Separately
Cephalon Inc. told a Pennsylvania federal court Wednesday that two remaining False Claims Act cases against it for off-label promotion should not be consolidated, arguing that since the relators' Fentora claims have been dismissed, they no longer share common matters of fact.
-
October 10, 2014
Off-Label Claims In Cephalon FCA Suits Trimmed By Judge
A Pennsylvania federal judge on Thursday trimmed allegations from two False Claims Act complaints accusing Cephalon Inc. of promoting painkiller Fentora and other drugs for off-label uses, finding that whistleblowers parroted earlier allegations.